- 标题
- 摘要
- 关键词
- 实验方案
- 产品
-
Deep transfer learning-based prostate cancer classification using 3 Tesla multi-parametric MRI
摘要： Purpose The purpose of the study was to propose a deep transfer learning (DTL)-based model to distinguish indolent from clinically significant prostate cancer (PCa) lesions and to compare the DTL-based model with a deep learning (DL) model without transfer learning and PIRADS v2 score on 3 Tesla multi-parametric MRI (3T mp-MRI) with whole-mount histopathology (WMHP) validation. Methods With IRB approval, 140 patients with 3T mp-MRI and WMHP comprised the study cohort. The DTL-based model was trained on 169 lesions in 110 arbitrarily selected patients and tested on the remaining 47 lesions in 30 patients. We compared the DTL-based model with the same DL model architecture trained from scratch and the classification based on PIRADS v2 score with a threshold of 4 using accuracy, sensitivity, specificity, and area under curve (AUC). Boot-strapping with 2000 resamples was performed to estimate the 95% confidence interval (CI) for AUC. Results After training on 169 lesions in 110 patients, the AUC of discriminating indolent from clinically significant PCa lesions of the DTL-based model, DL model without transfer learning and PIRADS v2 score C 4 were 0.726 (CI [0.575, 0.876]), 0.687 (CI [0.532, 0.843]), and 0.711 (CI [0.575, 0.847]), respectively, in the testing set. The DTL-based model achieved higher AUC compared to the DL model without transfer learning and PIRADS v2 score C 4 in discriminating clinically significant lesions in the testing set. Conclusion The DeLong test indicated that the DTL-based model achieved comparable AUC compared to the classification based on PIRADS v2 score (p = 0.89).
关键词： Whole-mount histopathology,Multi-parametric MRI,Prostate cancer,Deep learning,Clinically significant lesion classification,PIRADS v2 score
更新于2025-09-10 09:29:36
-
Past and Present of Imaging Modalities Used for Prostate Cancer Diagnosis: Androgen Receptor Targeted Imaging of Prostate Cancer as a Future Modality for Early, Rapid and Efficient Diagnosis
摘要： Background: Prostate cancer is the second most prevailing cancer among men worldwide. In the most cases, prostate cancer is slowly progressing, whereas, in some cases, it is a rapidly progressing disease leading to the significantly high mortality rate. Thus, there is still demand for prostate-specific imaging in order to provide image-guided early diagnosis and for the provision of patient-specific therapy. Discussion: Besides discussing traditional diagnostic approaches, this review illustrates a perspective on prostate cancer imaging summarizing current imaging approaches with a special focus on Prostate Specific Membrane Antigen (PSMA), Bombesin (BN) and Androgen Receptor (AR) targeted imaging using Positron Emission Tomography (PET) and Single Positron Emission Computed Tomography (SPECT) based on 99mTc and other radiotracers. Here, the prostate biology is reconsidered for nuclear imaging as future modality for early, rapid and efficient diagnosis of prostate cancer. Conclusion: Future direction in prostate cancer imaging involves the development of androgen receptor based imaging using nonsteroidal antiandrogen agent for early diagnosis of prostate cancer.
关键词： single photon emission computed tomography,Prostate cancer,patient-specific therapy,radiotracer,positron-emission tomography,prostate-specific membrane antigen
更新于2025-09-09 09:28:46
-
Assessment of 68Ga-PSMA-11 PET positivity predictive factors in prostate cancer
摘要： Purpose: Positron emission tomography (PET) studies with 68Ga-PSMA-11 (68Ga-HBED-CC-PSMA) have earned the attention of researchers, due to overexpression of PSMA in the tumoral tissues of prostate cancer. Our aim was to analyze the potential benefit of this radiotracer in the biochemical relapse of prostate cancer. Material and methods: This retrospective analysis included 53 studies, performed on 50 male prostate cancer patients referred due to biochemical recurrence. In all cases, previous imaging techniques were negative or inconclusive. Results: Of the 53 studies, 36 (68%) were positive. Significant differences were found between the positive and negative PET groups in Gleason’s scale, PSA levels, PSAdt, late acquisition and the administration of androgen deprivation therapy during treatment (p < .05). Regarding PSA levels, 10 (48%) of the 21 patients with PSA < 1 ng/ml, obtained a pathological PET result. When the PSAdt was below six months, 86.7% of the patients obtained an abnormal PET. In the multivariate analysis, only Gleason’s scale was associated independently with an abnormal PET result. Conclusions: 68Ga-PSMA-11 PET shows a high disease detection rate in patients where other techniques showed negative or doubtful images. Almost 50% of patients with prostate cancer biochemical recurrence and low PSA levels (<1 ng/ml) have active disease on 68Ga-PSMA-11 PET, precisely where other radiotracers lack sensitivity.
关键词： Prostate-specific membrane antigen,68Ga-PSMA-11,Prostate cancer,Positron emission tomography
更新于2025-09-09 09:28:46
-
Comparison of [68Ga]Ga-PSMA-HBED-CC PET versus Whole-Body Bone Scintigraphy for the Detection of Bone Metastases in Patients with Prostate Cancer
摘要： Aim: To compare [68Ga]Ga-PSMA-HBED-CC PET and (99m)Tc-DPD bone scintigraphy for the detection of bone metastases from prostate cancer. Methods: [68Ga]Ga-PSMA-HBED-CC PET/CT and (99m)Tc-DPD bone scintigraphy in 19 men with histopathological proven prostate cancer were compared to each other for the sensitivity/specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for the detection of bone metastases. Results: According to the standard of reference lesion-based analysis of [68Ga]Ga-PSMA-HBED-CC PET and (99m)Tc-DPD bone scintigraphy reached a sensitivity of 45.6%/34%, specificity of 86.4%/81.4%, accuracy of 60.5%/51.2%, positive predictive value of 85.5%/76.1%, and negative predictive value of 47.7%/41.4%, respectively. Conclusion: [68Ga]Ga-PSMA-HBED-CC PET could detect significantly more bone metastases in prostate cancer than (99m)Tc-DPD bone scintigraphy.
关键词： Bone metastases,Prostate cancer,(99m)Tc-DPD scintigraphy,[68Ga]Ga HBED-CC PSMA,Detection rate
更新于2025-09-09 09:28:46
-
[IEEE 2018 IEEE International Conference on Imaging Systems and Techniques (IST) - Krakow, Poland (2018.10.16-2018.10.18)] 2018 IEEE International Conference on Imaging Systems and Techniques (IST) - Computer-Aided Diagnosis of Prostate Cancer on Diffusion Weighted Imaging: A Technical Review
摘要： Worldwide, prostate cancer is one of the most diagnosed cancer of males. However, developing efficient diagnostic techniques for prostate cancer is very essential and has a great clinical impact. These techniques can enhance the benefits from treatment and improve the chance of patients’ survival. Although, Transrectal Ultrasound (TRUS) guided biopsy is still the standard approach for prostate cancer diagnosing, it is not preferred due to its invasiveness. Therefore, there is a necessity to explore non-invasive methods that can detect the prostate cancer early. Several magnetic resonance imaging (MRI), e.g. T2 MRI, dynamic contrast-enhanced (DCE)- MRI, and diffusion weighted imaging (DWI), have been vastly utilized for prostate cancer detection. The main goal of this paper is to provide an overview of latest non-invasive Computer Aided Diagnosis (CAD) systems for diagnosing their prostate using DWI, highlighting experiments, implementation, and reported results. Moreover, the paper outlines the challenges of present diagnostic systems, and presents the current trends in solving these challenges.
关键词： DWI,Prostate cancer,CAD
更新于2025-09-09 09:28:46
-
SERS-Based Quantification of PSMA in Tissue Microarrays Allows Effective Stratification of Patients with Prostate Cancer
摘要： Prostate specific membrane antigen (PSMA), a type II membrane protein, is an attractive biomarker that has been validated clinically for the diagnosis of prostate cancer. In this study, we developed surface-enhanced Raman scattering (SERS) nanoprobes for PSMA detection and quantification at the single-cell level on prostate cancer cells. The cells were targeted employing SERS nanoprobes that consisted of gold nanostars functionalized with PSMA aptamer molecules. We were able to quantify picomolar concentrations of soluble PSMA protein and used the resulting calibration curve to estimate the expression of PSMA on the surface of the prostate cancer cell, LNCaP, at the single-cell level. Importantly, we employed these SERS tags to stratify prostate cancer patients by assessing PSMA expression in tissues contained in a prostate tissue microarray. The stratification results clearly correlated PSMA expression to recommended therapy groups, rendering the described method as an effective tool to aid in designing personalized therapeutic protocols. Benchmarking detection sensitivity against immunofluorescence staining and comparing stratification results obtained with the two methods allowed us to validate our novel approach against standard practices. On the basis of these results, we confirm the validity of PSMA as an effective biomarker for prostate cancer patient evaluation and propose SERS-based diagnostic techniques as integrative methods for the assessment of disease stage and the identification of effective therapeutic protocols.
关键词： aptamer,tissue microarray,surface-enhanced Raman scattering,PSMA,Prostate specific membrane antigen,SERS,nanoprobes,prostate cancer,biomarker,gold nanostars
更新于2025-09-04 15:30:14
-
Metabolic Volumetric Parameters in <sup>11</sup> C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer
摘要： Purpose. Positron emission tomography/magnetic resonance imaging (PET/MRI) can facilitate the use of noninvasive imaging biomarkers in clinical prostate cancer staging. Although multiparametric MRI is a widely used technique, the clinical value of simultaneous PET imaging remains unclear. This study aimed at investigating this issue. Methods. Between January 2015 and December 2016, 31 high-risk prostate cancer patients underwent 11C-choline PET/MRI for staging purposes. Clinical characteristics and imaging parameters, including the standardized uptake value (SUV) and metabolic volumetric parameters from PET imaging; apparent diffusion coefficient (ADC) values from diffusion-weighted imaging; and volume transfer rate constant (Ktrans), reflux rate constant (Kep), and initial area under curve (iAUC) in 60 seconds from dynamic contrast-enhanced (DCE) MRI were analyzed. Results. 11C-Choline PET imaging parameters were significantly correlated with prostate-specific antigen (PSA) levels, and metabolic volumetric parameters, including metabolic tumor volume (MTV) and uptake volume product (UVP), showed significant correlations with other MRI parameters. In our cohort analysis, the PET/MRI parameters UVP/minimal ADC value (ADCmin) and kurtosis of Kep (Kepkur)/ADCmin were significant predictors for progression-free survival (PFS) (HR = 1.01, 95% CI: 1.00–1.02, p = 0.031 and HR = 1.09, 95% CI: 1.02–1.16, p = 0.009, respectively) in multivariate Cox regression analysis. High UVP/ADCmin and Kepkur/ADCmin values were significantly associated with shorter PFS. Conclusions. Metabolic volumetric parameters such as MTV and UVP can be routinely used as PET imaging biomarkers to add prognostic value and show better correlations in combination with MR imaging parameters in high-risk prostate cancer patients undergoing 11C-choline PET/MRI.
关键词： 11C-choline,metabolic volumetric parameters,imaging biomarkers,PET/MRI,prostate cancer
更新于2025-09-04 15:30:14
-
Separation of Biological Particles in a Modular Platform of Cascaded Deterministic Lateral Displacement Modules
摘要： Deterministic lateral displacement (DLD) has been extensively implemented in the last decade for size-based sample preparation, owing to its high separation performances for a wide range of particle dimensions. However, separating particles from 1 μm to 10 μm in one single DLD device is challenging because of the required diversity of pillar dimensions and inherent fabrication issues. This paper presents an alternative approach to achieve the extraction of E. coli bacteria from blood samples spiked with prostate cancer cells. Our approach consists in cascading individual DLD devices in a single automated platform, using flexible chambers that successively collect and inject the sample between each DLD stage without any external sample manipulation. Operating DLD separations independently enables to maximize the sorting efficiency at each step, without any disturbance from downstream stages. The proposed two-step automated protocol is applied to the separation of three types of components (bacteria, blood particles and cancer cells), with a depletion yield of 100% for cancer cells and 93% for red blood cells. This cascaded approach is presented for the first time with two DLD modules and is upscalable to improve the dynamic range of currently available DLD devices.
关键词： Deterministic lateral displacement,DLD,blood samples,E. coli,prostate cancer cells,particle separation,microfluidic
更新于2025-09-04 15:30:14
-
Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
摘要： Ex vivo studies have shown that the gastrin releasing peptide receptor (GRPr) is overexpressed on almost all primary prostate cancers, making it a promising target for prostate cancer imaging and targeted radiotherapy. Methods: Biodistribution, dosimetry and tumor uptake of the GRPr antagonist 64Cu-CB-TE2A-AR06 [(64Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)-PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-LeuNH2] were studied by PET/CT in four patients with newly diagnosed prostate cancer (T1c-T2b, Gleason 6-7). Results: No adverse events were observed after injection of 64Cu-CB-TE2A-AR06. Three of four tumors were visualized with high contrast [tumor-to-prostate ratio > 4 at 4 hours (h) post injection (p.i.)], one small tumor (T1c, < 5% tumor on biopsy specimens) showed moderate contrast (tumor-to-prostate ratio at 4 h: 1.9). Radioactivity was cleared by the kidneys and only the pancreas demonstrated significant accumulation of radioactivity, which rapidly decreased over time. Conclusion: 64Cu-CB-TE2A-AR06 shows very favorable characteristics for imaging prostate cancer. Future studies evaluating 64Cu-CB-TE2A-AR06 PET/CT for prostate cancer detection, staging, active surveillance, and radiation treatment planning are necessary.
关键词： Gastrin releasing peptide receptor,bombesin,prostate cancer,PET/CT
更新于2025-09-04 15:30:14